<?xml version="1.0" encoding="UTF-8"?>
<p id="Par9">A phase III, randomized, open-label, multicenter trial (NCT04324021) evaluating the efficacy and safety of anakinra and emapalumab, an anti-interferon (IFN)-Î³ antibody, in the treatment of hyperinflammatory syndrome caused by the cytokine storm commenced on 2 April 2020 (NCT04324021). Although the subcutaneous formulation is the only US FDA-approved dosage form of anakinra [
 <xref ref-type="bibr" rid="CR16">16</xref>], the dosage form being investigated in the ongoing trial is by intravenous infusion [
 <xref ref-type="bibr" rid="CR20">20</xref>]. Other noncomparative, open-label studies underway in Greece (NCT04356366, NCT04339712) and Belgium (NCT04330638) are using the subcutaneous form.
</p>
